Psychedelic trials often exclude real-world comorbidities; clinicians must weigh blinding limits, dosing durability, support needs, safety risks, and uneven system readiness.

A systematic review and meta-analysis compares pharmacological agents with nonpharmacologic approaches to identify the most effective interventions for insomnia in peri- and postmenopausal women.

GLP-1 drugs may quiet cravings by reshaping brain reward and satiety signals, reducing food-seeking drive and binge-like eating, while long-term effects remain unclear.

When an antidepressant seems to stop working, the patient’s deterioration is real. The explanation may be less certain.

An endocrinologist warns psychiatrists against overreading peripheral thyroid hormones and flags kelp and T3 microdosing as underrecognized risks.

Adjustment disorder often goes undiagnosed after major life stressors, especially in cancer care; learn updated criteria, risks, and emerging therapies like psilocybin.

Ketamine or esketamine during C-section anesthesia lowers early postpartum depression symptom scores in trials, hinting at a new prevention approach under study.

Real-world data show TRD costs spike during resistant episodes; Compass’ psilocybin COMP360 delivers durable symptom relief through 26 weeks, potentially easing resource strain.